Latest Capital Markets News

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Finder Energy’s KTJ offshore development in Timor-Leste has achieved a key milestone with an independent classification of 22.2 million barrels of 2P reserves, underpinning its push toward a Final Investment Decision.

Dexus (ASX: DXS) reported steady FY26 results with AFFO of 45.0 cents per security and distributions of 37.0 cents, while initiating a strategic review of infrastructure funds following an adverse APAC court judgment.

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

Cuscal Limited reported a 49% jump in statutory profit after tax to $42.7 million for FY26, driven by strategic acquisitions of Indue and Paymark that expanded its Australian and New Zealand footprint. The company declared a fully franked 7-cent final dividend and expects mid-twenties percentage growth in underlying profit and transaction volumes for FY27.

Fortescue Ltd delivered a record 201.3 million tonnes of iron ore in FY26, alongside a 3% rise in underlying net profit after tax to US$3.47 billion, despite a significant $750 million impairment charge on its Iron Bridge asset. The miner declared a fully franked final dividend of A$0.46 per share and continues to advance its ambitious decarbonisation and growth agenda.

Heartland Group Holdings delivered a striking 140% jump in net profit for FY2026, underpinned by margin gains and asset quality improvements, while advancing a transformative merger with TSB to create a major New Zealand challenger bank.

NZX Limited reported a robust first half of 2026 with operating earnings up 9.4% and net profit rising 18%. The exchange strengthened its funds management and wealth administration arms, relaunched equity derivatives, and declared a higher interim dividend. A new CEO is set to take the helm in September.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

Patriot Resources has locked in a $3 million placement to fund exploration at its flagship Tassa silver-gold project in Peru and a new copper discovery in Zambia, underpinning its strategy to grow high-grade mineral resources.

Marquee Resources has launched an eight-hole reverse circulation drilling program at its Yindi Gold Project, focusing on a statistically refined central corridor to test for primary gold mineralisation beneath transported cover.

Credit Clear appoints Joshua Reid as Managing Director and interim CEO of ARMA Group Holdings, signaling a leadership shift aligned with its growth ambitions across Australia and international markets.